Thalidomide and thalidomide analogues in treatment of patients with inflammatory bowel disease: Meta-analysis

Table 1 Summary of included studies

Study/yr	Country	Patients No. (intervention/control)	Mean age (intervention/control)	Gender (male/female)	Participants
Luo/2008	China	23/23	37.2/36.5	27/19	Aged 18 to 70 yr, with mild-to-moderate CD
Lazzerini/2013	Italy	28/26	14.0/15.0	32/22	Aged 2 to 18 yr with active CD
Mansfield/2007	United Kingdom	23/28	41.5/41.3	21/30	Aged 18 to 75 yr with moderately severe CD
		33/28	37.5/41.3	33/29

CD: Crohn’s disease.

Table 2 Summary of included studies

Study/yr	Intervention	Control	Remission (intervention/control)	Response (intervention/control)	Adverse effects (intervention/control)
Luo/2008	Thalidomide100 mg/d	SASP	6/5	15/13	10/9
		4 g/d
Lazzerini/2013	Thalidomide 50, 100 and 150 mg/d	Unknown	3/13	5/5	Unknown/1
Mansfield/2007	lenalidomide 25 mg ⁄d,	Unknown	2/7	4/4	10/18
	lenalidomide 5 mg ⁄d		10/7	6/4	12/10